The proteolysis targeting chimera GMB-475 combined with dasatinib for the treatment of chronic myeloid leukemia with BCR::ABL1 mutants

Overview of attention for article published in Frontiers in Pharmacology, October 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (57th percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 6 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 9,919 followers.

RT @Trankill34: The proteolysis targeting chimera GMB-475 combined with dasatinib for the treatment of chronic myeloid leukemia with BCR::A…

21 Oct 2022

Reply Repost Favourite

The proteolysis targeting chimera GMB-475 combined with dasatinib for the treatment of chronic myeloid leukemia with BCR::ABL1 mutants https://t.co/2GEoPfssk6 https://t.co/iBWFzW1mOm

21 Oct 2022

Reply Repost Favourite

The proteolysis targeting chimera GMB-475 combined with dasatinib for the treatment of chronic myeloid leukemia with BCR::ABL1 mutants https://t.co/qVrjn5Exx9

20 Oct 2022

Reply Repost Favourite

New Research: The proteolysis targeting chimera GMB-475 combined with dasatinib for the treatment of chronic myeloid leukemia with BCR::ABL1 mutants https://t.co/JBeX4yVdaT #pharmacology

04 Oct 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.